Fate Therapeutics (FATE) Tops Q2 EPS by 7c

Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.30), $0.07 better than the analyst estimate of ($0.37).

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Key things to know ahead of SK Hynix’s blockbuster US listing
• ImmuCell reports 11.5% sales rise in Q2 2026, 20.9% gain for first half
• Sempra names new CFO and SoCalGas CEO amid infrastructure deal